Kiniksa Pharmaceuticals, Ltd.
Kiniksa is a small-cap biopharmaceutical company with minimal political engagement and no material government dependence, focused on rare inflammatory diseases.
BusinessWhat KNSA does
Kiniksa develops and commercializes therapies for rare inflammatory conditions, including autoinflammatory diseases and other specialty indications. Revenue derives primarily from product sales of approved therapies; the company has minimal government contract revenue and operates in the specialty pharma segment.
Lifetime Government AwardsKNSA federal contracts
KNSA doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding KNSA
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills to WatchLegislation flagged by our analysis
Political ProfileWhere KNSA sits in Washington
Kiniksa has no measurable political trading activity, minimal lobbying footprint, and no named legislative winners/losers. Stock movement driven primarily by clinical trial results and FDA decisions rather than political events.
Regulatory ExposureThreats & opportunities
Regulatory threats
- FDA approval delays
- Medicare pricing pressure
- drug pricing legislation
Regulatory opportunities
- orphan drug exclusivity extension
- accelerated approval pathways
- rare disease tax credits
Live signals + predictions for KNSA — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades KNSA
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord